Unless otherwise specified, the chemical reagents and laboratory equipment used in this study were obtained from Sigma Chemical Co. (St. Louis, MO, USA) and SPL Life Sciences (Pocheon, Korea), respectively. General Bio compound K-10 mg solution (GBCK10S) was generated by General Bio Co., Ltd. (Wanju, Korea) via enzymatic bioconversion. Reference ginsenosides including ginsenoside-Rb1, -Rb2, -Rc, -Rd, -Re, -F1, -F2, -Rg3 (20S), compound O (CO), compound Y (CY), and CK were purchased from the Ambo Institute (Daejeon, Korea).
We purchased 5-week-old female C57BL/6 mice from the Koatech Laboratory Animal Center (Pyeongtaek, Korea). These mice were maintained under specific pathogen-free conditions with food and water provided ad libitum. Each experimental group of 10 mice was administered a 0 mg, 100 mg, or 200 mg sample/kg body weight/day for 4 weeks. Animal experiments were approved by the Institutional Animal Care and Use Committee of Jeonbuk National University (Approval No. JBNU 2020-0161) and the committee's guidelines were followed throughout the protocol.
We purchased 5-week-old female C57BL/6 mice from the Koatech Laboratory Animal Center (Pyeongtaek, Korea). These mice were maintained under specific pathogen-free conditions with food and water provided ad libitum. Each experimental group of 10 mice was administered a 0 mg, 100 mg, or 200 mg sample/kg body weight/day for 4 weeks. Animal experiments were approved by the Institutional Animal Care and Use Committee of Jeonbuk National University (Approval No. JBNU 2020-0161) and the committee's guidelines were followed throughout the protocol.